Synergistic effect of hydralazine associated with triazoles on Candida spp. in planktonic cells

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. da Matta DA, Souza ACR, Colombo AL. Revisiting species distribution and antifungal susceptibility of Candida bloodstream isolates from Latin American medical centers. J. Fungi 3(2), 11–17 (2017). • Shows epidemiology of candidemia in Latin America.
  Google Scholar
• 2. Yo C-H, Hsein Y-C, Wu Y-L et al. Clinical predictors and outcome impact of community-onset polymicrobial bloodstream infection. Int. J. Antimicrob. Agents 54(6), 716–722 (2019).
  Medline CASGoogle Scholar
• 3. Marins TA, Marra AR, Edmond MB et al. Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital. BMC Infect. Dis. 18(1), 187 (2018).
  MedlineGoogle Scholar
• 4. Firacative C. Invasive fungal disease in humans: are we aware of the real impact? Mem. Inst. Oswaldo Cruz 115(9), e200430 (2020).
  Medline CASGoogle Scholar
• 5. Magill SS, O'Leary E, Janelle SJ et al. Changes in prevalence of health care-associated infections in US hospitals. N. Engl. J. Med. 379(18), 1732–1744 (2018).
  MedlineGoogle Scholar
• 6. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J. Antimicrob. Chemother. 73(January), i4–i13 (2018).
  Medline CASGoogle Scholar
• 7. Braga PR, Cruz IL, Ortiz I, Barreiros G, Nouér SA, Nucci M. Secular trends of candidemia at a Brazilian tertiary care teaching hospital. Brazilian J. Infect. Dis. 22(4), 273–277 (2018).
  MedlineGoogle Scholar
• 8. Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm. Pathog. Dis. 74(4), ftw018 (2016).
  MedlineGoogle Scholar
• 9. Lai C, Chen S, Ko W, Hsueh P. Increased antimicrobial resistance during the COVID-19 pandemic. Int. J. Antimicrob. Agents. 57(4), 106324 (2020).
  Google Scholar
• 10. Parvathaneni V, Kulkarni NS, Muth A, Gupta V. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov. Today 24(10), 2076–2085 (2019).
  Medline CASGoogle Scholar
• 11. Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. Nat. Microbiol. 4(4), 565–577 (2019).
  Medline CASGoogle Scholar
• 12. Ruiz-Magaña MJ, Martínez-Aguilar R, Lucendo E, Campillo-Davo D, Schulze-Osthoff K, Ruiz-Ruiz C. The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells. Oncotarget 7(16), 21875–21886 (2016). • Shows that hydralazine causes cell death via mitochondrial apoptotic pathway and causes DNA damage.
  MedlineGoogle Scholar
• 13. Melton D, Lewis CD, Price NE, Gates KS. Covalent adduct formation between the antihypertensive drug hydralazine and abasic sites in double- and single-stranded DNA. Chem. Res. Toxicol. 27(12), (2014).
  MedlineGoogle Scholar
• 14. M27-A3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard (3rd Edition). Clinical and Laboratory Standards Institute, PA, USA (2008).
  Google Scholar
• 15. M27-S4 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Clinical and Laboratory Standards Institute. PA, USA (2012).
  Google Scholar
• 16. De Bona EAM, da Silva Pinto FG, Fruet TK, Jorge TCM, de Moura AC. Comparação de métodos para avaliação da atividade antimicrobiana e determinação da concentração inibitória mínima (cim) de extratos vegetais aquosos e etanólicos. Arq. Inst. Biol. (Sao Paulo) 81(3), (2014).
  Google Scholar
• 17. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52(1), 1 (2003).
  Medline CASGoogle Scholar
• 18. Neto JBA, da Silva CR, Neta MAS et al. Antifungal activity of naphthoquinoidal compounds in vitro against fluconazole-resistant strains of different Candida species: a special emphasis on mechanisms of action on Candida tropicalis. PLoS ONE 9(5), (2014).
  Google Scholar
• 19. Cavalcanti BC, Bezerra DP, Magalhães HIF et al. Kauren-19-oic acid induces DNA damage followed by apoptosis in human leukemia cells. J. Appl. Toxicol. 29(7), 560–568 (2009).
  Medline CASGoogle Scholar
• 20. Da Silva AR, De Andrade Neto JB, Da Silva CR et al. Berberine antifungal activity in fluconazole-resistant pathogenic yeasts: action mechanism evaluated by flow cytometry and biofilm growth inhibition in Candida spp. Antimicrob. Agents Chemother. 60(6), 3551–3557 (2016).
  MedlineGoogle Scholar
• 21. Csizmadia P. MarvinSketch and MarvinView: molecule applets for the world wide web. Proceedings of The 3rd International Electronic Conference on Synthetic Organic Chemistry. p1775 (2019).
  Google Scholar
• 22. López R. Capillary surfaces with free boundary in a wedge. Adv. Math. (NY) 262, 476–483 (2014).
  Google Scholar
• 23. Halgren TA. Merck molecular force fieldI. Basis, form, scope, parameterization, andperformance of MMFF94. J. Comput. Chem. 17(5), 490–519 (1996).
  CASGoogle Scholar
• 24. Trincao J, Johnson RE, Escalante CR, Prakash S, Prakash L, Aggarwal AK. Structure of the catalytic core of S. cerevisiae DNA polymerase η: implications for translesion DNA synthesis. Mol. Cell 8(2), 417–426 (2001).
  Medline CASGoogle Scholar
• 25. Znosko BM, Kennedy SD, Wille PC, Krugh TR, Turner DH. Structural features and thermodynamics of the J4/5 loop from the Candida albicans and Candida dubliniensis group I introns. Biochemistry 43(50), 15822–15837 (2004).
  Medline CASGoogle Scholar
• 26. Yu EY, Sun J, Lei M, Lue NF. Analyses of Candida Cdc13 orthologues revealed a novel OB fold dimer arrangement, dimerization-assisted DNA binding, and substantial structural differences between Cdc13 and RPA70. Mol. Cell. Biol. 32(1), 186–198 (2012).
  Medline CASGoogle Scholar
• 27. Gleason JE, Galaleldeen A, Peterson RL et al. Candida albicans SOD5 represents the prototype of an unprecedented class of Cu-only superoxide dismutases required for pathogen defense. Proc. Natl Acad. Sci. USA 111(16), 5866–5871 (2014).
  Medline CASGoogle Scholar
• 28. Cutfield JF, Sullivan PA, Cutfield SM. Minor structural consequences of alternative CUG codon usage (Ser for Leu) in Candida albicans exoglucanase. Protein Eng. 13(10), 735–738 (2000).
  Medline CASGoogle Scholar
• 29. Van Den Berg B, Chembath A, Jefferies D, Basle A, Khalid S, Rutherford JC. Structural basis for Mep2 ammonium transceptor activation by phosphorylation. Nat. Commun. 7, 1–11 (2016).
  Google Scholar
• 30. Hargrove TY, Friggeri L, Wawrzak Z et al. Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. J. Biol. Chem. 292(16), 6728–6743 (2017).
  Medline CASGoogle Scholar
• 31. Singh SB, Kaelin DE, Wu J et al. Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (part-2). Bioorganic Med. Chem. Lett. 25(9), 1831–1835 (2015).
  Medline CASGoogle Scholar
• 32. Lange C, Nett JH, Trumpower BL, Hunte C. Specific roles of protein–phospholipid interactions in the yeast cytochrome bc1 complex structure. EMBO J. 20(23), 6591–6600 (2001).
  Medline CASGoogle Scholar
• 33. Huey R, Morris GM, Forli S. Using AutoDock 4 and AutoDock Vina with AutoDockTools: a tutorial. Scripps Res. Inst. Mol. (December), 32 (2012).
  Google Scholar
• 34. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31(2), 455–461 (2009).
  Google Scholar
• 35. Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. Chem. 25(13), 1605–1612 (2004).
  Medline CASGoogle Scholar
• 36. Machado E, Neto DA, Silva J, Rocha C, Coelho B, Silva E. Virtual screening based on molecular docking of possible inhibitors ofCovid-19 main protease. Microbial Pathogenesis 148, 104365 (2020).
  MedlineGoogle Scholar
• 37. Yusuf D, Davis AM, Kleywegt GJ, Schmitt S. An alternative method for the evaluation of docking performance: RSR vs RMSD. J. Chem. Inf. Model. 48(7), 1411–1422 (2008).
  Medline CASGoogle Scholar
• 38. Kadela-Tomanek M, Jastrzębska M, Marciniec K, Chrobak E, Bębenek E, Boryczka S. Lipophilicity, pharmacokinetic properties, and molecular docking study on sars-cov-2 target for betulin triazole derivatives with attached 1,4-quinone. Pharmaceutics 13(6), 781 (2021).
  MedlineGoogle Scholar
• 39. Campitelli M, Zeineddine N, Samaha G, Maslak S. Combination antifungal therapy: a review of current data. J. Clin. Med. Res. 9(6), 451–456 (2017).
  Medline CASGoogle Scholar
• 40. Ramage G, Martínez JP, López-Ribot JL. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 6(7), 979–986 (2006).
  Medline CASGoogle Scholar
• 41. do AV Sá LG, da Silva CR, de S Campos R et al. Synergistic anticandidal activity of etomidate and azoles against clinical fluconazole-resistant Candida isolates. Future Microbiol. 14(17), 1477–1488 (2019).
  Google Scholar
• 42. Król J, Nawrot U, Bartoszewicz M. Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole. J. Mycol. Med. 28(2), 327–331 (2018).
  Medline CASGoogle Scholar
• 43. Ji H, Zhang W, Zhou Y et al. A three-dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals. J. Med. Chem. 43(13), 2493–2505 (2000).
  Medline CASGoogle Scholar
• 44. Sevrioukova IF. Apoptosis-inducing factor: structure, function, and redox regulation. Antioxidants Redox Signal. 14(12), 2545–2579 (2011).
  Medline CASGoogle Scholar
• 45. Lee W, Lee DG. A novel mechanism of fluconazole: fungicidal activity through dose-dependent apoptotic responses in Candida albicans. Microbiology 164(2), 194–204 (2018).
  Medline CASGoogle Scholar
• 46. Lima MTNS, dos Santos LB, Bastos RW, Nicoli JR, Takahashi JA. Antimicrobial activity and acetylcholinesterase inhibition by extracts from chromatin modulated fungi. Brazilian J. Microbiol. 49(1), 169–176 (2018).
  Medline CASGoogle Scholar
• 47. Wuyts J, Van Dijck P, Holtappels M. Fungal persister cells: the basis for recalcitrant infections? PLoS Pathog. 14(10), 1–14 (2018).
  Google Scholar
• 48. Ruma YN, Keniya MV, Tyndall JDA, Monk BC. Characterisation of Candida parapsilosis CYP51 as a drug target using Saccharomyces cerevisiae as host. J. Fungi 8(1), 69 (2022). • Suggests that CYP51 as a target of antifungals can overcome the resistance of pathogenic fungi to existing azole drugs.
  CASGoogle Scholar
• 49. de Assis LJ, Bain JM, Liddle C et al. Nature of β-1,3-glucan-exposing features on Candida albicans cell wall and their modulation. MBio 13(6), 1–19 (2022). • Shows that b-1,3-glucan exposed in Candida is the target of phagocytic attack and that lactate-induced masking reduces exposure and phagocytosis.
  CASGoogle Scholar
• 50. Candelaria M, Gallardo-Rincón D, Arce C et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann. Oncol. 18(9), 1529–1538 (2007).
  Medline CASGoogle Scholar
• 51. Candelaria M, Burgos S, Ponce M, Espinoza R, Dueñas-Gonzalez A. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS). Ann. Hematol. 96(11), 1825–1832 (2017). •• Study on the repurpose of hydralazine in anticancer therapy.
  Medline CASGoogle Scholar
• 52. Ranjan K, Brandão F, Morais JAV et al. The role of Cryptococcus neoformans histone deacetylase genes in the response to antifungal drugs, epigenetic modulators and to photodynamic therapy mediated by an aluminium phthalocyanine chloride nanoemulsion in vitro. J. Photochem. Photobiol. B Biol. 216, 112131 (2021).
  Medline CASGoogle Scholar
• 53. Li X, Cai Q, Mei H et al. The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans. J. Antimicrob. Chemother. 70(7), 1993–2003 (2015).
  Medline CASGoogle Scholar